Roche's New Avastin Studies Not as Good as Early Data, FDA Says

July 16 (Bloomberg) -- Roche Holding AG’s top-seller Avastin didn’t slow breast tumors in new studies as much as in earlier data used to win approval, according to U.S. regulators weighing whether to permit continued sales for this use.

Back to news